A preclinical study shows that MEF2D-rearranged primary cells are sensitive to panobinostat, a HDAC inhibitor (HDACi), probably through the inhibition of HDAC9, which is overexpressed in MEF2D-rearranged B-ALL, offering a possible therapeutic option for MEF2D-rearranged ALL [47]. This evidence concerns the gene MEF2D and acute lymphoblastic leukemia.